On July 30, 2026, Instinct Bio Technical Company Holdings Inc. announced a strategic collaboration with Invitrx Therapeutics, Inc., to expand its GENRÊVER cosmetic brand into the United States and explore regenerative medicine opportunities in Indonesia. The partnership leverages Instinct Bio's proprietary formulations and Invitrx's U.S. GMP manufacturing capabilities for product commercialization, while also evaluating the supply of concentrated exosomes and conditioned media for Indonesian clinics. This framework builds upon a six-year existing commercial relationship between the parties. As a biotechnology company focused on regenerative medicine, longevity-related technologies, and advanced therapeutic platforms, Instinct Bio aims to strengthen its international growth through these new market entries.

Instinct Bio announced an agreement with Dr. Mario Damianus Daniel Hadinoto to launch its Japanese aesthetic brand, GENRÊVER CLINIC, in Indonesia via a subscription-model membership beauty clinic business. The company plans an initial investment of approximately US$1 million to establish five directly operated clinics in major metropolitan areas including Jakarta, Surabaya, Bandung, Medan, and Bali. This initiative aims to create a recurring-revenue platform with transparent pricing and flexible cancellation terms, serving as a strategic gateway to the Company’s core regenerative medicine business involving stem-cell and iPS-cell technologies. Instinct Bio is a biotechnology company focused on regenerative medicine, longevity-related technologies, and advanced therapeutic platforms.

Instinct Bio Technical Company Holdings Inc. announced on July 28, 2026, that it has entered into an indicative term sheet for a proposed equity purchase facility allowing the sale of up to US$150 million of common stock over three years. The facility provides the company with the right, but not the obligation, to direct share purchases based on volume-weighted average price less a specified discount. Proceeds are intended to accelerate the development of its regenerative medicine platform, fund working capital, and pursue strategic acquisitions. This transaction is not yet finalized and depends on executing definitive documents and satisfying conditions. Instinct Bio is a biotechnology company focused on regenerative medicine, longevity-related technologies, and advanced therapeutic platforms.